# Genomic Outcomes of Metformin

> **NCT02986659** · PHASE4 · COMPLETED · sponsor: **Wake Forest University Health Sciences** · enrollment: 30 (actual)

## Conditions studied

- Coronary Artery Disease
- Mild Cognitive Impairment
- Obesity, Abdominal
- Hypertension

## Interventions

- **DRUG:** Metformin
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02986659
- **Lead sponsor:** Wake Forest University Health Sciences
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-08-03
- **Primary completion:** 2018-11-15
- **Final completion:** 2018-11-15
- **Target enrollment:** 30 (ACTUAL)
- **Last updated:** 2023-11-18

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02986659

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02986659, "Genomic Outcomes of Metformin". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT02986659. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*